FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2074530471> ?p ?o ?g. }

• W2074530471 abstract "British Journal of Cancer (2005) 93, 266. doi:10.1038/sj.bjc.6602693 www.bjcancer.comPublished online 12 July 2005& 2005 Cancer Research UKSir,In their concise review on evolving treatment strategies formyeloma, Morgan and Davies (2005) stated that ‘early death was,and still is, a significant problem, and addressing the causes of thisis important including early diagnosis, the treatment of infection,hydration and the choice of the most appropriate chemotherapy’.The most common presenting symptoms of the disease are fatigue,bone pain and recurrent infections. The latest classificationsystem, recently released from The International Myeloma Work-ing Group (2003), highlighted the importance to distinguishbetween asymptomatic and overt myeloma, because only thelatter requires active treatment. According to this statement, thebiological activity of the disease, more than the tumour mass,is the foremost guide to the therapy. The related organ or tissueimpairment (ROTI) that meets the criterion for the diagnosisconsists of hypercalcemia, renal insufficiency, anaemia or bonelesions (a group of findings referred to as CRAB). However, weneed to understand that some of the clinical features of the disease,as the degree of anaemia, are not completely explained by theplasma cellular infiltrates or paraprotein secretion. Althoughuncommonly, myeloma can present as fever of unknown origin(FUO) (Mueller et al, 2002; Lambotte et al, 2003). In these cases thefever is attributable to the disease itself, and indeed no infectionsare demonstrable, even with extensive work-up. Moreover, thefever cannot be abated with antibiotics although chemotherapyworks well (Mumoli et al, 2004). It is not already known if themodulation of the interaction between the neoplastic clone andthe marrow microenvironment, as is the case during therapywith bortezomib, could reverse this kind of presentation; thiscould in turn result in delaying chemotherapy, at least in patientsnot eligible for transplantation procedures. Morgan and Daviesconclude saying that in the future it will be desirable to describemyeloma as a treatable disease with prolonged survival andgood quality of life if the correct treatment decisions are made.We agree with this and we add, moreover, if the correct diagnosishas also been made. We therefore suggest that FUO shouldbe mentioned as an indication for diagnosis and therapy inmyeloma patients." @default.
• W2074530471 created "2016-06-24" @default.
• W2074530471 creator A5055292769 @default.
• W2074530471 date "2005-07-01" @default.
• W2074530471 modified "2023-10-09" @default.
• W2074530471 title "Multiple myeloma and fever of unknown origin: a need for therapy" @default.
• W2074530471 cites W1984408098 @default.
• W2074530471 cites W2053035653 @default.
• W2074530471 cites W2110562918 @default.
• W2074530471 cites W2155452415 @default.
• W2074530471 cites W2164807675 @default.
• W2074530471 doi "https://doi.org/10.1038/sj.bjc.6602693" @default.
• W2074530471 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2361557" @default.
• W2074530471 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16012526" @default.
• W2074530471 hasPublicationYear "2005" @default.
• W2074530471 type Work @default.
• W2074530471 sameAs 2074530471 @default.
• W2074530471 citedByCount "1" @default.
• W2074530471 crossrefType "journal-article" @default.
• W2074530471 hasAuthorship W2074530471A5055292769 @default.
• W2074530471 hasBestOaLocation W20745304711 @default.
• W2074530471 hasConcept C121608353 @default.
• W2074530471 hasConcept C126322002 @default.
• W2074530471 hasConcept C16005928 @default.
• W2074530471 hasConcept C177713679 @default.
• W2074530471 hasConcept C2776139714 @default.
• W2074530471 hasConcept C2776364478 @default.
• W2074530471 hasConcept C2777910003 @default.
• W2074530471 hasConcept C2779134260 @default.
• W2074530471 hasConcept C2779310458 @default.
• W2074530471 hasConcept C71924100 @default.
• W2074530471 hasConceptScore W2074530471C121608353 @default.
• W2074530471 hasConceptScore W2074530471C126322002 @default.
• W2074530471 hasConceptScore W2074530471C16005928 @default.
• W2074530471 hasConceptScore W2074530471C177713679 @default.
• W2074530471 hasConceptScore W2074530471C2776139714 @default.
• W2074530471 hasConceptScore W2074530471C2776364478 @default.
• W2074530471 hasConceptScore W2074530471C2777910003 @default.
• W2074530471 hasConceptScore W2074530471C2779134260 @default.
• W2074530471 hasConceptScore W2074530471C2779310458 @default.
• W2074530471 hasConceptScore W2074530471C71924100 @default.
• W2074530471 hasLocation W20745304711 @default.
• W2074530471 hasLocation W20745304712 @default.
• W2074530471 hasLocation W20745304713 @default.
• W2074530471 hasLocation W20745304714 @default.
• W2074530471 hasOpenAccess W2074530471 @default.
• W2074530471 hasPrimaryLocation W20745304711 @default.
• W2074530471 hasRelatedWork W111334434 @default.
• W2074530471 hasRelatedWork W1984408098 @default.
• W2074530471 hasRelatedWork W2015971406 @default.
• W2074530471 hasRelatedWork W2053035653 @default.
• W2074530471 hasRelatedWork W2153525933 @default.
• W2074530471 hasRelatedWork W2413642622 @default.
• W2074530471 hasRelatedWork W2435227317 @default.
• W2074530471 hasRelatedWork W2802828592 @default.
• W2074530471 hasRelatedWork W3094341023 @default.
• W2074530471 hasRelatedWork W41985691 @default.
• W2074530471 isParatext "false" @default.
• W2074530471 isRetracted "false" @default.
• W2074530471 magId "2074530471" @default.
• W2074530471 workType "article" @default.